CoChat

Redefining Colorectal Cancer by Tumor Biology

Salem, Mohamed E., Puccini, Alberto, Tie, Jeanne · 2020 · American Society of Clinical Oncology Educational Book

The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.

Abstract

Colorectal cancer treatment has undergone a paradigm shift. We no longer see this disease as a singular, anatomic tumor type but rather a set of disease subgroups. Largely because of a better understanding of cancer biology and the introduction and integration of molecular biomarkers—the premise of precision therapy—we are beginning to direct treatments toward the right tumor target(s) in the right patients. The field of molecular profiling is continually evolving, and new biomarkers are constantly being discovered that have investigational, therapeutic, and/or prognostic implications—negative or positive. To date, only a few biomarkers have sufficient actionable, clinical implication to earn international guideline-recommended routine testing. Hence, it is vital that the treating oncologist should know which biomarkers to assess, when in the treatment course to test for them, and how the test is to be done. Correct interpretation of profiling results is imperative. Herein, we focus on international guideline-recommended mutation testing for patients prior to their colorectal cancer treatment initiation. The clinical applications of circulating tumor DNA (ctDNA) in patients with metastatic disease, based on our current knowledge and capabilities, are also addressed.

Overview

Integrity signals

Registry

Crossref · 10.1200/edbk_279867

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 12

  1. Gutierrez ME, 2019, Precision Oncol, 3, 1
  2. Gupta R, 2020, J Clin Oncol, 38
  3. Pennell NA, 2019, Precision Oncol, 3, 1
  4. 10.1186/s13059-014-0454-7 · doi:10.1186/s13059-014-0454-7 · Paper page
  5. Mandel P, 1948, C R Seances Soc Biol Fil, 142, 241
  6. Sorenson GD, 1994, Cancer Epidemiol Biomarkers Prev, 3, 67
  7. Battaglin F, 2018, Clin Adv Hematol Oncol, 16, 735
  8. Thomas J, Clin Colorectal Cancer
  9. Lenz H-J, 2019, J Clin Oncol, 37
  10. Kopetz S, 2017, J Clin Oncol, 35
  11. Nakamura Y, 2019, Ann Oncol, 30, v198
  12. Sartore-Bianchi A, 2019, Ann Oncol, 30, v851

Cited by

See all 14

Metadata

Authors
Salem, M. E., Puccini, A., & Tie, J.
Affiliations
  • Levine Cancer Institute (US)
  • Ospedale Policlinico San Martino (IT)
  • Walter and Eliza Hall Institute of Medical Research (AU)
Corresponding author
Salem, Mohamed E.
Venue
American Society of Clinical Oncology Educational Book
Published
2020-05
Volume
40
Issue
40
Pages
147-159
ISSN
  • 1548-8748 (ISSN-L)
  • 1548-8756
OpenAlex
W3012562659
Cited by
14
References
108
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 6 · 2021: 3 · 2020: 2
FWCI
1.08
Type
journal article
Language
en
Open access
closed
Locations
  • American Society of Clinical Oncology Educational Book (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
colorectal cancer, molecular biomarkers, precision oncology, molecular profiling, mutation testing, circulating tumor DNA, metastatic colorectal cancer, tumor subtypes, prognostic factors, actionable biomarkers
MeSH terms
Biology, Female, Humans, Male, Prognosis, Colorectal Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.